Herbalife's Q3 Sales Up, Net Income Dips; YTD Profit Surges

TL;DR

**Herbalife's Q3 is a red flag, with sales up but profit down, despite a strong year-to-date net income, signaling potential operational headwinds.**

AI Summary

Herbalife Ltd. reported a mixed financial performance for the three and nine months ended September 30, 2025. For the three months, net sales increased to $1,273.7 million from $1,240.3 million in the prior year, a 2.7% rise. However, net income attributable to Herbalife decreased to $43.2 million, down from $47.4 million in the same period of 2024, representing a 9.07% decline. Diluted EPS also fell to $0.42 from $0.46. For the nine months, net sales slightly decreased to $3,754.5 million from $3,785.7 million, a 0.82% dip. Despite this, net income attributable to Herbalife significantly increased to $142.9 million from $76.4 million in the prior year, a substantial 87.04% improvement, driven by lower selling, general, and administrative expenses and other operating income. Cash and cash equivalents decreased to $305.5 million as of September 30, 2025, from $415.3 million at December 31, 2024. The company also saw an increase in inventories to $512.5 million from $475.4 million, and receivables, net, rose to $97.8 million from $68.9 million. Long-term debt, net of current portion, increased to $1,997.2 million from $1,976.6 million.

Why It Matters

Herbalife's mixed results present a complex picture for investors. While the nine-month net income surge to $142.9 million is positive, the Q3 net income decline and increased inventory levels could signal underlying challenges in sales velocity and operational efficiency. The competitive landscape in the nutrition and direct selling industry remains intense, with new entrants and evolving consumer preferences. Employees and distributors might face pressure if sales growth doesn't consistently translate into higher commissions or stable business conditions. For customers, product availability and pricing could be affected by inventory management. The broader market will watch if Herbalife can sustain its year-to-date profit growth amidst declining cash reserves and rising debt.

Risk Assessment

Risk Level: medium — The risk level is medium due to declining cash and cash equivalents, which fell from $415.3 million at December 31, 2024, to $305.5 million at September 30, 2025. Additionally, inventories increased to $512.5 million from $475.4 million, and long-term debt, net of current portion, rose to $1,997.2 million from $1,976.6 million, indicating potential liquidity and working capital pressures.

Analyst Insight

Investors should closely monitor Herbalife's inventory turnover and cash flow generation in upcoming quarters. A deeper dive into the drivers of the Q3 net income decline, despite higher sales, is warranted. Consider the impact of increased debt on future interest expenses and profitability.

Financial Highlights

debt To Equity

N/A

revenue

$3.75B

operating Margin

9.65%

total Assets

$2.70B

total Debt

$2.02B

net Income

$142.9M

eps

$1.38

gross Margin

78.24%

cash Position

$305.5M

revenue Growth

-0.82%

Key Numbers

• $1.27B — Q3 2025 Net Sales (Increased from $1.24B in Q3 2024, showing a 2.7% growth.)
• $43.2M — Q3 2025 Net Income (Decreased from $47.4M in Q3 2024, a 9.07% decline.)
• $3.75B — YTD 2025 Net Sales (Slightly decreased from $3.79B in YTD 2024, a 0.82% dip.)
• $142.9M — YTD 2025 Net Income (Significantly increased from $76.4M in YTD 2024, an 87.04% improvement.)
• $0.42 — Q3 2025 Diluted EPS (Decreased from $0.46 in Q3 2024.)
• $1.38 — YTD 2025 Diluted EPS (Increased from $0.75 in YTD 2024.)
• $305.5M — Cash and Cash Equivalents (Decreased from $415.3M at December 31, 2024.)
• $512.5M — Inventories (Increased from $475.4M at December 31, 2024.)
• $1.99B — Long-Term Debt (net of current portion) (Increased from $1.97B at December 31, 2024.)
• 103.3M — Common Shares Outstanding (As of October 29, 2025, up from 101.2M at December 31, 2024.)

Key Players & Entities

• HERBALIFE LTD. (company) — registrant
• New York Stock Exchange (regulator) — exchange where HLF is registered
• $1,273.7 million (dollar_amount) — net sales for three months ended September 30, 2025
• $43.2 million (dollar_amount) — net income attributable to Herbalife for three months ended September 30, 2025
• $3,754.5 million (dollar_amount) — net sales for nine months ended September 30, 2025
• $142.9 million (dollar_amount) — net income attributable to Herbalife for nine months ended September 30, 2025
• $305.5 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $512.5 million (dollar_amount) — inventories as of September 30, 2025
• $1,997.2 million (dollar_amount) — long-term debt, net of current portion, as of September 30, 2025
• FASB (regulator) — Financial Accounting Standards Board

FAQ

Risk Factors

• Regulatory Scrutiny and Compliance [high — regulatory]: Herbalife operates in a highly regulated industry, facing scrutiny over its business model, marketing practices, and product claims. Changes in regulations, particularly in key markets, could significantly impact sales and operations. For instance, the company has previously faced investigations and settlements related to its multi-level marketing structure.
• Competition and Market Saturation [high — market]: The direct selling and health supplement market is intensely competitive, with numerous players offering similar products. Increased competition can lead to pricing pressures and a need for higher marketing spend, potentially impacting margins. The company's reliance on independent distributors also exposes it to shifts in consumer preferences and the attractiveness of alternative sales channels.
• Supply Chain and Inventory Management [medium — operational]: Maintaining adequate inventory levels is crucial, but also presents risks. Inventories increased to $512.5 million as of September 30, 2025, from $475.4 million at December 31, 2024. Disruptions in the supply chain, changes in raw material costs, or an inability to sell existing inventory could negatively affect financial performance.
• Debt Levels and Interest Expense [high — financial]: Herbalife carries significant long-term debt, which stood at $1,997.2 million (net of current portion) as of September 30, 2025, an increase from $1,976.6 million at year-end 2024. High debt levels increase financial risk, particularly in a rising interest rate environment, as evidenced by the $51.0 million in net interest expense for Q3 2025.
• Distributor Network Stability [medium — operational]: The company's success is heavily dependent on its network of independent distributors. Changes in distributor recruitment, retention, or productivity, as well as potential shifts in the appeal of the distributor model, pose a significant operational risk. The increase in common shares outstanding to 103.2 million from 101.2 million suggests potential equity dilution or stock-based compensation activity.
• Liquidity and Cash Flow [medium — financial]: Cash and cash equivalents decreased to $305.5 million as of September 30, 2025, from $415.3 million at December 31, 2024. While not critically low, this reduction, coupled with increased receivables ($97.8 million from $68.9 million), warrants monitoring for potential impacts on short-term liquidity and operational flexibility.

Industry Context

Herbalife operates in the global direct selling industry, primarily focused on nutrition, weight management, and personal care products. This sector is characterized by intense competition from other direct selling companies, as well as traditional retail and e-commerce channels. Key trends include a growing consumer focus on health and wellness, but also increasing regulatory scrutiny of multi-level marketing business models worldwide.

Regulatory Implications

The direct selling model employed by Herbalife is subject to significant regulatory oversight in many jurisdictions. Concerns often revolve around distributor compensation structures, product claims, and consumer protection. Changes in regulations regarding pyramid schemes or marketing practices could necessitate costly business model adjustments or lead to fines and penalties.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the Q3 and YTD financial results, showing mixed sales and income trends, and changes in balance sheet items like cash, inventory, and debt.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of balance sheet items as of September 30, 2025, including cash, inventory, and long-term debt.
• 2024-09-30: End of Third Quarter 2024 — Prior year comparable period for Q3 2025 results, highlighting a 2.7% increase in net sales but a 9.07% decrease in net income.

Glossary

Royalty overrides

Payments made by the company to its distributors based on the sales volume of distributors in their downline. This is a key component of the multi-level marketing compensation structure. (Represents a significant cost of sales and a core element of Herbalife's business model, impacting gross profit and operating expenses.)

Operating lease right-of-use assets

Assets recognized under accounting standards for leases, representing the right to use an asset (like property) over the lease term. (Reflects the company's long-term rental commitments for facilities and offices, impacting the balance sheet and depreciation expenses.)

Marketing-related intangibles and other intangible assets, net

Non-physical assets arising from marketing efforts, brand recognition, or other acquired rights, net of accumulated amortization. (Represents value derived from brand and marketing activities, which are crucial for a direct-selling company like Herbalife.)

Accumulated deficit

The cumulative net losses of a company since its inception, less any cumulative net income. (Indicates that Herbalife has historically incurred more losses than profits, though the deficit narrowed significantly in the nine months ended September 30, 2025.)

Noncontrolling interest

The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership interest of outside shareholders in the consolidated entity. (Indicates that Herbalife has consolidated a subsidiary where it does not own 100% of the equity, which appeared in the current period.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Herbalife reported a modest 2.7% increase in Q3 net sales, but a 9.07% decline in net income, indicating margin pressure in the quarter. For the nine months, net sales saw a slight dip of 0.82%, yet net income surged by 87.04%, primarily due to significant reductions in selling, general, and administrative expenses and the recognition of other operating income. Balance sheet items show a decrease in cash and equivalents and an increase in inventories and long-term debt, suggesting a tightening liquidity position and increased financial leverage.

Key Financial Figures

• $0.0005 — registered: Common Shares, par value $0.0005 per share HLF New York Stock Exchan

Filing Documents

• hlf-20250930.htm (10-Q) — 3554KB
• hlf-ex10_49.htm (EX-10.49) — 55KB
• hlf-ex10_50.htm (EX-10.50) — 52KB
• hlf-ex31_1.htm (EX-31.1) — 10KB
• hlf-ex31_2.htm (EX-31.2) — 10KB
• hlf-ex32_1.htm (EX-32.1) — 5KB
• hlf-ex32_2.htm (EX-32.2) — 5KB
• 0001193125-25-267001.txt ( ) — 17379KB
• hlf-20250930.xsd (EX-101.SCH) — 1861KB
• hlf-20250930_htm.xml (XML) — 4268KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Unaudited Condensed Consolidated Balance Sheets 3 Unaudited Condensed Consolidated Statements of Income 4 Unaudited Condensed Consolidated Statements of Comprehensive Income 5 Unaudited Condensed Consolidated Statements of Cash Flows 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 56 Item 4.

Controls and Procedures

Controls and Procedures 59

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 62 Item 1A.

Risk Factors

Risk Factors 62 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 63 Item 3. Defaults Upon Senior Securities 63 Item 4. Mine Safety Disclosures 63 Item 5. Other Information 63 Item 6. Exhibits 63 2

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements HERBALIFE LTD. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, 2025 December 31, 2024 (in millions, except share and par value amounts) ASSETS Current assets: Cash and cash equivalents $ 305.5 $ 415.3 Receivables, net of allowance for doubtful accounts 97.8 68.9 Inventories 512.5 475.4 Prepaid expenses and other current assets 190.4 184.1 Total current assets 1,106.2 1,143.7 Property, plant, and equipment, at cost, net of accumulated depreciation and amortization 456.7 460.2 Operating lease right-of-use assets 171.7 185.7 Marketing-related intangibles and other intangible assets, net 315.7 312.3 Goodwill 101.0 87.7 Deferred income tax assets 401.7 398.6 Other assets 144.2 139.9 Total assets $ 2,697.2 $ 2,728.1 LIABILITIES AND SHAREHOLDERS' DEFICIT Current liabilities: Accounts payable $ 88.1 $ 70.0 Royalty overrides 345.8 334.1 Current portion of long-term debt 20.7 283.5 Other current liabilities 545.3 542.8 Total current liabilities 999.9 1,230.4 Long-term debt, net of current portion 1,997.2 1,976.6 Non-current operating lease liabilities 157.0 169.5 Other non-current liabilities 149.1 152.7 Total liabilities 3,303.2 3,529.2 Commitments and contingencies Shareholders' deficit: Common shares, $ 0.0005 par value; 2.0 billion shares authorized; 103.2 million (2025) and 101.2 million (2024) shares outstanding 0.1 0.1 Paid-in capital in excess of par value 304.6 278.2 Accumulated other comprehensive loss ( 251.6 ) ( 271.4 ) Accumulated deficit ( 665.1 ) ( 808.0 ) Total Herbalife shareholders' deficit ( 612.0 ) ( 801.1 ) Noncontrolling interest 6.0 — Total shareholders' deficit ( 606.0 ) ( 801.1 ) Total liabilities and shareholders' deficit $ 2,697.2 $ 2,728.1 See the accompanying